Second-Line Agents in the Treatment of Rheumatic Diseases

Abstract

Part 1 Evaluation and use of second-line agents: distinction between NSAIDs, corticosteroids and second-line agents, J.P. Famaey variable disease and variable response to second-line agents, G. David Champion and Malcolm L. Handel problems in the design and interpretation of trials of second-line agents, Ken J. Bulpitt and Harold E. Paulus assessment procedures for monitoring second-line agents, Paul W. Thompson predictors of risk from the use of second-line agents in rheumatoid arthritis, Alan J. Silman decision making - the choice of second-line agents in the United States, Bonnie Hepburn decision making - the choice of second-line agents in Europe and the United Kingdom, T. Pullar decision making - the choice of second-line agents in Australia, P.M. Brooks et al comments on decision making - the choice of second-line agents, Daniel E. Furst. Part 2 Second-line agents in the treatment of rheumatoid arthritis: gold therapy - a choice in the 1990s, H.A. Capell and H. Torley penicillamine, J.K. van der Korst and A.O. Muijsers purine analogs, Robert J.R. McKendry antimalarials, R.I. Rynes sulfonamides, Deborah E. Bax methotrexate, D. Mathers and A.S. Russell cyclosprin, W.B. Harrison alkylating agents, P.J. Clements. Part 3 Second-line agents in the treatment of other arthritides: second-line agents in osteoarthritis, Peter Ghosh et al treatment of seronegative polyarthritis, V. Neumann and V. Wright second-line agents in systemic lupus erythematosus, Mary Betty Stevens and Carol M. Ziminski second-line treatment of crystal-induced synovitis, J.T. Scott second-line agents in the treatment of systemic vasculitis, A.S.M. Jawad and D.G.I. Scott. Part 4 Second-line agents in the future: combination chemotherapy for rheumatoid arthritis, P.T. Dawes and M.J. Davis trace element supplements for inflammatory disease, M.W. Whitehouse new immunosuppressive agents, immune modulators and other drugs, Alan J. Lewis and Richard P. Carlson.